Share this article
Share this article
NEW YORK, Feb. 18, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn s disease and ulcerative colitis. Hoth executed an option agreement with Isoprene Pharmaceuticals, Inc. ( Isoprene ) to investigate the potential for the HT-003 API as an IBD therapeutic. Isoprene is a University of Maryland, Baltimore New Venture Initiative start-up company.
IBDs represent a large health burden in the United States, affecting approximately 3 million adults age 18 years and older that continues to increase each year.
-in
-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii)
RHB-107 (
upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv)
RHB-104, with positive results from a first Phase 3 study for Crohn s disease; (v)
RHB-102 (
Bekinda
®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi)
RHB-
106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.
Share this article
Share this article
DURHAM, N.C., Feb. 17, 2021 /PRNewswire/ EmitBio Inc., today announced statistically significant efficacy results from its randomized, placebo-controlled, double-blind Phase I/II clinical trial. The study was conducted with an investigational treatment device that directs precise wavelengths of safe, visible light targeted to the back of the throat and surrounding tissues. The device is designed for self-treatment of COVID-19 in an at-home setting. EmitBio™ achieved clinically and statistically significant results in both the reduction of SARS-CoV-2 viral load and accelerated time to symptom resolution in adults with COVID-19.
Light inactivates SARS-CoV-2 The ability to show statistical significance on both viral load and symptom endpoints with this sample size is a direct illustration of just how powerful our light treatment device can be, stated Nate Stasko, PhD, Chief Scientific Officer at EmitBio.
Bionic Vision Technologies Advances Clinical Program With AU$1 million Medical Research Future Fund Grant
News provided by
Share this article
Share this article
MELBOURNE, Australia, Feb. 16, 2021 /PRNewswire/ Bionic Vision Technologies (BVT) has started work on the next phase of development for its world-leading Australian bionic eye technology thanks to a recent Australian Government grant to refine its vision processing algorithms.
BVT s bionic eye is designed for people with the inherited retinal disease retinitis pigmentosa for which there is no current cure.
Clinical study data from patients implanted with the device show the prosthesis is safe and gives significant improvements to functional vision and quality of life. Users reported an improved awareness of external objects and surroundings.
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single ag